Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.

Autor: Makkouk A; Adicet Therapeutics, Menlo Park, California, USA., Yang XC; Adicet Therapeutics, Menlo Park, California, USA., Barca T; Adicet Therapeutics, Menlo Park, California, USA., Lucas A; Adicet Therapeutics, Menlo Park, California, USA., Turkoz M; Adicet Therapeutics, Menlo Park, California, USA., Wong JTS; Adicet Therapeutics, Menlo Park, California, USA., Nishimoto KP; Adicet Therapeutics, Menlo Park, California, USA., Brodey MM; Adicet Therapeutics, Menlo Park, California, USA., Tabrizizad M; Adicet Therapeutics, Menlo Park, California, USA., Gundurao SRY; Adicet Therapeutics, Menlo Park, California, USA., Bai L; Adicet Therapeutics, Menlo Park, California, USA., Bhat A; Adicet Therapeutics, Menlo Park, California, USA., An Z; Adicet Therapeutics, Menlo Park, California, USA., Abbot S; Adicet Therapeutics, Menlo Park, California, USA., Satpayev D; Adicet Therapeutics, Menlo Park, California, USA., Aftab BT; Adicet Therapeutics, Menlo Park, California, USA., Herrman M; Adicet Therapeutics, Menlo Park, California, USA mherrman@adicetbio.com.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Dec; Vol. 9 (12).